Andere Sprachen Savara Inc.

Aktien

A2DQ2B

US8051111016

SVRA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 14.05.2024			% 5 Tage	% 1. Jan.
4,81 ^USD	+4,79 %		-8,56 %	+2,34 %

09.05.	Savara Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
12.04.	Dr. Ricky Sun informiert den Verwaltungsrat von Savara Inc. über seine Absicht, sich nicht zur Wiederwahl zu stellen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Savara Reports First Quarter 2024 Financial Results and Provides Business Update	09.05.
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Savara to Present at the Citizens JMP Life Sciences Conference	07.05.
Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection	12.04.
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024	08.04.
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024	08.04.
Savara Announces New Employment Inducement Grant	25.03.
Savara Announces New Employment Inducement Grant	22.03.
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update	07.03.
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
Savara to Present at the Barclays 26th Annual Global Healthcare Conference	06.03.
Savara Announces New Employment Inducement Grant	02.02.
Savara to Present at Two Upcoming Healthcare Conferences	31.01.
Savara Insider Sold Shares Worth $395,900, According to a Recent SEC Filing	29.12.
Savara Insider Sold Shares Worth $442,291, According to a Recent SEC Filing	29.12.
Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis	22.12.
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	21.12.
Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis	21.12.
Savara Added to the NASDAQ Biotechnology Index	20.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Savara Inc.

Aktien

A2DQ2B

US8051111016

SVRA

Andere Sprachen

Filter